TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy
Nievergall, E, Reynolds, J, Kok, C H, Watkins, D B, Biondo, M, Busfield, S J, Vairo, G, Fuller, K, Erber, W N, Sadras, T, Grose, R, Yeung, D T, Lopez, A F, Hiwase, D K, Hughes, T P, White, D L
Published in Leukemia (01.06.2016)
Published in Leukemia (01.06.2016)
Get full text
Journal Article
Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia
Schafranek, L, Nievergall, E, Powell, J A, Hiwase, D K, Leclercq, T, Hughes, T P, White, D L
Published in Leukemia (01.01.2015)
Published in Leukemia (01.01.2015)
Get full text
Journal Article
Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment
Yeung, D T, Moulton, D J, Heatley, S L, Nievergall, E, Dang, P, Braley, J, Branford, S, Moore, S, Mullighan, C G, Hughes, T P, White, D L
Published in Leukemia (01.01.2015)
Published in Leukemia (01.01.2015)
Get full text
Journal Article
Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL
Trahair, T N, Lock, R B, Sutton, R, Sia, K C S, Evans, K, Richmond, J, Law, T, Venn, N C, Irving, J A, Moore, S, Nievergall, E, Dang, P, Heatley, S L, White, D L, Revesz, T
Published in Bone marrow transplantation (Basingstoke) (01.09.2016)
Published in Bone marrow transplantation (Basingstoke) (01.09.2016)
Get full text
Journal Article
P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY‐DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH‐RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG‐HD7 TRIAL
Mai, E. K., Bertsch, U., Fenk, R., Tichy, D., Besemer, B., Dürig, J., Schroers, R., Metzler, I., Hänel, M., Mann, C., Asemissen, A. M., Heilmeier, B., Nievergall, E., Huhn, S., Kriegsmann, K., Weinhold, N., Luntz, S., Holderrried, T. A. W., Trautmann‐Grill, K., Gezer, D., Klaiber‐Hakimi, M., Müller, M., Khandanpour, C., Knauf, W., Scheid, C., Munder, M., Geer, T., Riesenberg, H., Thomalla, J., Hoffmann, M., Raab, M. S., Salwender, H. J., Weisel, K. C., Goldschmidt, H.
Published in HemaSphere (23.06.2022)
Published in HemaSphere (23.06.2022)
Get full text
Journal Article
Adam Meets Eph: An ADAM Substrate Recognition Module Acts as a Molecular Switch for Ephrin Cleavage In trans
Janes, Peter W., Saha, Nayanendu, Barton, William A., Kolev, Momchil V., Wimmer-Kleikamp, Sabine H., Nievergall, Eva, Blobel, Carl P., Himanen, Juha-Pekka, Lackmann, Martin, Nikolov, Dimitar B.
Published in Cell (21.10.2005)
Published in Cell (21.10.2005)
Get full text
Journal Article
TGF-[alpha] and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy
Nievergall, E, Reynolds, J, Kok, C H, Watkins, D B, Biondo, M, Busfield, S J, Vairo, G, Fuller, K, Erber, W N, Sadras, T, Grose, R, Yeung, D T, Lopez, A F, Hiwase, D K, Hughes, T P, White, D L
Published in Leukemia (01.06.2016)
Published in Leukemia (01.06.2016)
Get full text
Journal Article
Xenograft-directed personalized therapy for a patient with post-transplant relapse of ALL
Trahair, T N, Lock, R B, Sutton, R, Sia, K C S, Evans, K, Richmond, J, Law, T, Venn, N C, Irving, J A, Moore, S, Nievergall, E, Dang, P, Heatley, S L, White, D L, Revesz, T
Published in Bone marrow transplantation (01.09.2016)
Published in Bone marrow transplantation (01.09.2016)
Get full text
Report